Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
News|Articles|September 4, 2026
AI's Evolving Role in Radiation Oncology
Author(s)Cancer Network Staff
How do we implement AI in a way that serves patients? Expert radiation oncologists discuss the crucial question.
Advertisement
Advertisement
Artificial intelligence (AI) has arrived in oncology not as a distant forecast but as a daily reality, shaping how notes are written, how tumor boards prepare, how treatment plans are optimized, and how patients navigate a system that was already formidably complex before algorithms entered the examination room. The question facing clinicians is no longer whether AI belongs in cancer care but how to deploy it rigorously, equitably, and without losing the irreplaceable human core of medicine.
Related to this article
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.
Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.
Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
Advertisement
Advertisement